Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer

This study has been completed.
Information provided by (Responsible Party):
Spectrum Pharmaceuticals, Inc Identifier:
First received: January 11, 2008
Last updated: May 26, 2015
Last verified: May 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2012
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: December 18, 2013